Clovis Oncology, Inc. (CLVS) is a publicly traded company in the Unknown sector. Across all available filings, 35 corporate insiders have executed 1000 transactions totaling $245.8M, demonstrating a bullish sentiment with $145.8M in net insider flow. The most recent transaction on Nov 2, 2022 involved a sale of 1,908 shares valued at $1.9K.
No significant insider buying has been recorded for CLVS in the recent period.
No significant insider selling has been recorded for CLVS in the recent period.
Based on recent SEC filings, insider sentiment for CLVS is bullish with an Insider Alignment Score of 80/100 and a net flow of $145.8M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Clovis Oncology, Inc. (CLVS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 35 insiders are actively trading CLVS stock, having executed 1000 transactions in the past 90 days. The most active insider is Parters VII L. P. Domain (Executive), who has made 6 transactions totaling $22.2M.
Get notified when executives and directors at CLVS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 2, 2022 | Rolfe Lindsey | Executive | Sale | 1,908 | $0.98 | $1.9K | |
| Nov 2, 2022 | Rolfe Lindsey | Executive | Sale | 2,353 | $0.98 | $2.3K | |
| Nov 2, 2022 | W. Muehl Daniel | Executive | Sale | 2,066 | $0.98 | $2.0K | |
| Nov 2, 2022 | W. Muehl Daniel | Executive | Sale | 2,513 | $0.98 | $2.5K | |
| Nov 2, 2022 | C. Harding Thomas | Executive | Sale | 788 | $0.98 | $772 | |
| Nov 2, 2022 | C. Harding Thomas | Executive | Sale | 915 | $0.98 | $897 | |
| Nov 2, 2022 | C. Harding Thomas | Executive | Sale | 63 | $0.98 | $62 | |
| Nov 2, 2022 | C. Ivers-read Gillian | Executive | Sale | 1,675 | $0.98 | $1.6K | |
| Nov 2, 2022 | C. Ivers-read Gillian | Executive | Sale | 2,006 | $0.98 | $2.0K | |
| Nov 2, 2022 | Edward Gross Paul | Executive | Sale | 2,595 | $0.98 | $2.5K | |
| Nov 2, 2022 | Edward Gross Paul | Executive | Sale | 2,135 | $0.98 | $2.1K | |
| Nov 1, 2022 | Rolfe Lindsey | Executive | Option Exercise | 3,749 | $N/A | $0 | |
| Nov 1, 2022 | Rolfe Lindsey | Executive | Option Exercise | 4,625 | $N/A | $0 | |
| Nov 1, 2022 | W. Muehl Daniel | Executive | Option Exercise | 5,623 | $N/A | $0 | |
| Nov 1, 2022 | W. Muehl Daniel | Executive | Option Exercise | 4,625 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 46 | $195.8M | 78.5% |
Sale(S) | 381 | $50.0M | 20.0% |
Payment(F) | 37 | $2.2M | 0.9% |
Exercise(M) | 321 | $1.5M | 0.6% |
Other(J) | 99 | $0 | 0.0% |
Gift(G) | 20 | $0 | 0.0% |
Award(A) | 1 | $0 | 0.0% |
Conversion(C) | 95 | $0 | 0.0% |
Insiders at Clovis Oncology, Inc. are accumulating shares at an accelerated pace. With 35 insiders making 1000 transactions totaling $195.8M in purchases versus $50.0M in sales, the net buying activity of $145.8M signals strong executive confidence. Parters VII L. P. Domain (Executive) leads the buying activity with $22.2M in transactions across all time.